Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron (Q37421187)

20 August 2017

1 reference

title

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron (English)

1 reference

20 August 2017

0 references

0 references

Tomás Simůnek

1

1 reference

20 August 2017

Martin Stérba

2

1 reference

20 August 2017

Olga Popelová

3

1 reference

20 August 2017

Michaela Adamcová

4

1 reference

20 August 2017

Radomír Hrdina

5

1 reference

20 August 2017

Vladimír Gersl

6

1 reference

20 August 2017

1 January 2009

1 reference

20 August 2017

Pharmacological Reports

1 reference

20 August 2017

61

1 reference

20 August 2017

1

1 reference

20 August 2017

154-171

1 reference

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic fromS. Peucetius var.caesius

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Adriamycin-induced oxidative mitochondrial cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracyclines: selected new developments

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Persistent Effects of Doxorubicin on Cardiac Gene Expression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Pyridoxal isonicotinoyl hydrazone and its analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Molecular and cellular mechanisms of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Genotyping the risk of anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin as an antioxidant: maintenance of myocardial levels of lycopene under doxorubicin treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Childhood cancer survival in Europe and the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline cardiotoxicity: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracyclines: cardiotoxicity and its prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The role of iron and iron chelators in anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

New iron chelators in anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Iron signaling and oxidant damage

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

HPLC study on stability of pyridoxal isonicotinoyl hydrazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Investigation of the stability of aromatic hydrazones in plasma and related biological material.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Does anthracycline administration by infusion in children affect late cardiotoxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Cardiotoxicity of antitumor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The role of reactive oxygen and nitrogen species in cellular iron metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Hydroxyl radical production and DNA damage induced by anthracycline-iron complex

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Chronic health conditions in adult survivors of childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Long-term and short-term models for studying anthracycline cardiotoxicity and protectors

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline cardiotoxicity in long-term survivors of childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH)

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Release of iron from ferritin by cardiotoxic anthracycline antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Structural aspects of antioxidant activity of flavonoids

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Cardioprotective interventions for cancer patients receiving anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

A phase I study of monohydroxyethylrutoside in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Molecular pharmacology of the interaction of anthracyclines with iron

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Chelation and mobilization of cellular iron by different classes of chelators

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Doxorubicin-induced persistent oxidative stress to cardiac myocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970018-0

7 January 2021

10.1016/S1734-1140(09)70018-0

Identifiers

DOI

1 reference

20 August 2017

1 reference